Cue Biopharma, Inc. (CUE): Operating Cash Flow
-$21.69M
Year ended 2025-12-31
-$50.05M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$21.69M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$36.33M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$39.96M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$41.81M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$38.84M | n/m | 2023-03-21, From 2021-01-01 |
| 2020-12-31 | -$32.49M | n/m | 2022-03-16, From 2020-01-01 |
| 2019-12-31 | -$30.80M | n/m | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | -$26.41M | n/m | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | -$12.14M | n/a | 2019-03-14, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | -$21.69M | n/m |
| Celularity Inc (CELU) | 2025-12-31 | -$13.25M | n/m |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | -$128.51M | n/m |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | -$86.10M | n/m |
| Verastem, Inc. (VSTM) | 2025-12-31 | -$137.51M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | -$369.52M | n/m |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | -$17.65M | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | -$147.78M | n/m |
| Bioharvest Sciences Inc. (BHST) | 2025-12-31 | -$7.23M | n/m |
Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗